Drugmakers cut deals in price-inflation suit

Remember the legal wrangle over the price of cancer drugs? The lawsuit pitted insurers, patients, attorneys general--perhaps even a few kitchen sinks--against 30 drug companies, including GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, Schering Plough. At issue: Whether the companies artificially inflated drug prices, then sold the drugs to doctors at a discount, giving doctors the spread--and themselves an unfair advantage over competitors who weren't playing the game (though with so many companies allegedly involved, who wasn't?).

The latest? GlaxoSmithKline settled for $70 million, and Bristol-Myers and AstraZeneca are cutting deals. In June, a judge found Bristol-Myers, AstraZeneca and Schering-Plough liable for the price inflation. No word yet on whether Schering-Plough is also negotiating a settlement.

- read this item from The Wall Street Journal

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.